Tempus Wealth Planning LLC Grows Stake in Bristol-Myers Squibb (NYSE:BMY)

Tempus Wealth Planning LLC grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 190.2% in the first quarter, Holdings Channel reports. The firm owned 11,318 shares of the biopharmaceutical company’s stock after purchasing an additional 7,418 shares during the period. Tempus Wealth Planning LLC’s holdings in Bristol-Myers Squibb were worth $614,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in BMY. Schonfeld Strategic Advisors LLC grew its position in shares of Bristol-Myers Squibb by 1,004.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 94,351 shares of the biopharmaceutical company’s stock valued at $5,476,000 after purchasing an additional 85,812 shares in the last quarter. Alps Advisors Inc. grew its position in shares of Bristol-Myers Squibb by 20.2% during the 3rd quarter. Alps Advisors Inc. now owns 106,263 shares of the biopharmaceutical company’s stock valued at $6,168,000 after purchasing an additional 17,825 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth $9,297,000. KPP Advisory Services LLC bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth $582,000. Finally, Seven Eight Capital LP lifted its holdings in shares of Bristol-Myers Squibb by 117.3% during the 3rd quarter. Seven Eight Capital LP now owns 54,207 shares of the biopharmaceutical company’s stock worth $3,146,000 after acquiring an additional 29,263 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Down 1.0 %

Shares of NYSE:BMY traded down $0.39 during midday trading on Thursday, hitting $40.06. 9,131,450 shares of the stock traded hands, compared to its average volume of 16,023,750. The stock has a market capitalization of $81.21 billion, a PE ratio of -12.92, a P/E/G ratio of 13.84 and a beta of 0.44. The business’s 50 day moving average is $42.46 and its two-hundred day moving average is $47.91. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a one year low of $39.63 and a one year high of $65.38.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the prior year, the firm posted $2.05 earnings per share. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. As a group, research analysts forecast that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.99%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BMY. BMO Capital Markets dropped their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, Barclays lowered their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.